ClinicalTrials.gg
CompletedNCT04709575Updated Oct 27, 2022Results posted

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

A Phase 3 interventional study of REGN5713 and REGN5714 in Allergic Rhinitis and Conjunctivitis, sponsored by Regeneron Pharmaceuticals. Completed at 37 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-27.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
353
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 141 studies in Rhinitis, Allergic with a site in United States — 5 open to participants now, 7 under way, none of them phase 3. Rhinitis, Allergic · United States.

Enrollment
27th of 119
353 · median 54
Started
2021
with 4 others
Phase 3
33 of 141
none open now
Registered
133rd of 141
by date

Among the 141 studies in Rhinitis, Allergic with a site in United States, this one is the 27th largest by enrollment of the 119 interventional ones that give a count, is one of 5 that started in 2021, is one of 33 in phase 3, and was the 133rd registered.

Rhinitis, Allergic

717 studies on the registry are indexed under Rhinitis, Allergic; 94 are open to participants now.

Browse Rhinitis, Allergic studies →

Open to participants now

5 of the 141 studies in Rhinitis, Allergic with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 54 Rhinitis, Allergic studies recruiting now, 11 (20%) set no upper age limit and 38 (70%) stop at 75 or younger; 22 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 141 studies in Rhinitis, Allergic with a site in United States, or all of them as a file.
02

Study summary

The primary objective is to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season after a single dose of REGN5713-5714-5715 versus placebo.

03

Conditions studied

  • Allergic Rhinitis
  • Conjunctivitis

Keywords

  • Birch Allergy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. Documented or participant-reported history of birch pollen-triggered allergic rhinitis symptoms, with or without conjunctivitis, for at least 2 years
  2. Positive Skin prick test (SPT) with birch pollen extract in the screening period, as defined in the protocol
  3. Positive Allergen-specific IgE (sIgE) tests for birch pollen and Bet v 1 in the screening period, as defined in the protocol
  4. Willing and able to comply with clinic visits and study-related procedures

Key Exclusion Criteria:

  1. Participation in a prior REGN5713-5714-5715 clinical trial
  2. Recurrent or chronic rhinitis or sinusitis not associated with birch pollen season, or due to daily contact with other allergens causing symptoms that are expected to coincide with birch pollen season, as assessed by the investigator
  3. Participants who anticipate major changes in allergen exposure in their home or work environments that are expected to coincide with the study assessments as assessed by the investigator
  4. Persistent chronic or recurring acute infection requiring treatment with antibiotics, antivirals, or antifungals, or any untreated respiratory infections (at the discretion of the investigator) within 4 weeks prior to screening visit. Participants may be re-evaluated for eligibility after symptoms resolve
  5. Documentation of active SARS-CoV-2 infection, as defined in the protocol
  6. A clinical history of asthma with 2 or more asthma exacerbations requiring hospitalizations or systemic in the previous year
  7. History of birch allergy immunotherapy as defined in the protocol
  8. Use of anti-IgE or other biological therapy in treatment of asthma or allergy within 6 months prior to screening

NOTE: Other protocol defined Inclusion/Exclusion Criteria apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
353 participants (actual)

Study arms

  • Experimental
    REGN5713-5714-5715

    REGN5713-5714-5715 administered subcutaneously

    Drug: REGN5713 · Drug: REGN5714 · Drug: REGN5715

  • Placebo comparator
    Placebo Only

    Placebo matching REGN5713-5714-5715 administered subcutaneously

    Drug: Placebo

Interventions

  • Administered subcutaneously

  • DrugREGN5714

    Administered subcutaneously

  • Administered subcutaneously

  • DrugPlacebo

    Placebo that replaces REGN5713-5714-5715

06

What researchers measure

Primary outcomes

  1. Combined Symptom and Medication Score (CSMS) in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo

    The average CSMS will be calculated based on daily symptom score and daily medication score recorded over the duration of the birch pollen season (BPS). CSMS is calculated by adding the Daily Medication Score (DMS) and Total Symptom Score (TSS) together, with scores ranging between 0 (none) and 38 (severe).

    Time frame: Until the end of Birch Pollen Season, up to Week 16

Secondary outcomes

  1. Total Symptom Score (TSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo

    TSS is a combined score of TOSS and TNSS. TNSS and TOSS are scored as in part 1 each for a combined TSS of 0 (none) to 18 (severe)

    Time frame: Until the end of Birch Pollen Season, up to Week 16

  2. Total Nasal Symptom Score (TNSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo

    Total nasal symptom score (TNSS) is from 0 to 12 and is based on assessment of 4 nasal symptoms graded on a Likert scale ranging from 0 (none) to 3 (severe) for congestion, itching, and rhinorrhea, and from 0 (none) to 3 (5 or more sneezes) for sneezing.

    Time frame: Until the end of Birch Pollen Season, up to Week 16

  3. Total Ocular Symptom Score (TOSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo

    Total ocular symptom score is 0 to 6 and is based on itching/redness/gritty feeling and tearing/watering; each of the 2 symptoms is graded 0 (absent), 1 (mild), 2 (moderate), and 3 (severe)

    Time frame: Until the end of Birch Pollen Season, up to Week 16

  4. Daily Medication Score (DMS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo

    The Daily Medication Score (DMS) is calculated by adding points for each pre-specified medication taken as follows: desloratadine 5 mg 6 points/dose; maximum daily score 6 points, olopatadine 1 mg/mL each drop 1.5 points/drop; maximum daily score 6 points, mometasone furoate 50 ug/dose 2.0 points/spray; maximum daily score 8 points). The scale is 0 (minimum) to 20 (maximum)

    Time frame: Until the end of Birch Pollen Season, up to Week 16

  5. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Throughout the Study

    Number of participants with any Treatment Emergent Adverse Events (TEAEs) from participating in study

    Time frame: Up to Day 127

  6. Number of Participants With Serious TEAEs Throughout the Study

    Number of participants with any Serious Treatment Emergent Adverse Events (TEAEs) from participating in study

    Time frame: Up to Day 127

  7. Change From Baseline to the End of Study in Birch SPT Mean Wheal Diameter in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo

    Number of participants who showed change from baseline to the end of the study in Birch Skin Prick Test (SPT) Mean Wheal Diameter, in participants who received REGN5713-5714-5715 compared to placebo

    Time frame: Baseline through Day 127

  8. Percent Change From Baseline to the End of Study in Birch SPT Mean Wheal Diameter in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo

    Time frame: Baseline through Day 127

  9. Serum Concentration of REGN5713 Over the Study Duration

    Time frame: Day 0, Day 56, Day 112

  10. Serum Concentration of REGN5714 Over the Study Duration

    Time frame: Up to Day 127

  11. Serum Concentration of REGN5715 Over the Study Duration

    Time frame: Up to Day 127

  12. Percentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5713 Throughout the Study

    Percentage of participants who developed antibodies to intervention provided during study

    Time frame: Up to Day 127

  13. Percentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5714 Throughout the Study

    Percentage of participants who developed antibodies to intervention provided during study

    Time frame: Up to Day 127

  14. Percentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5715 Throughout the Study

    Percentage of participants who developed antibodies to intervention provided during study

    Time frame: Up to Day 127

  15. Number of "Well Days"

    "Well Days" are defined as days when rescue medication is not utilized and the Total symptom score (TSS) is ≤2/18

    Time frame: Until the end of Birch Pollen Season, up to Week 16

07

Results

Posted Oct 27, 2022

Participant flow

Participant flow — Overall Study
MilestoneREGN5713-5714-5715Placebo Only
Started176177
Completed166172
Not completed105
Withdrew: Withdrawal by subject62
Withdrew: Lost to follow-up22
Withdrew: Adverse event10
Withdrew: Protocol violation11

Outcome measures

PrimaryCombined Symptom and Medication Score (CSMS) in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo

The average CSMS will be calculated based on daily symptom score and daily medication score recorded over the duration of the birch pollen season (BPS). CSMS is calculated by adding the Daily Medication Score (DMS) and Total Symptom Score (TSS) together, with scores ranging between 0 (none) and 38 (severe).

Time frame:
Until the end of Birch Pollen Season, up to Week 16
Reported as:
Least squares mean · Scores on a Scale
Combined Symptom and Medication Score (CSMS) in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo
Scores on a ScaleREGN5713-5714-5715Placebo Only
Combined Symptom and Medication Score (CSMS) in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo7.503 ± 0.65458.498 ± 0.6534
Statistical analysis
  • REGN5713-5714-5715 vs Placebo Only · LS Mean Difference · p = 0.0497 · Linear mixed-effect model: -0.995 · 95% CI -1.9886 to -0.0011
SecondaryTotal Symptom Score (TSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo

TSS is a combined score of TOSS and TNSS. TNSS and TOSS are scored as in part 1 each for a combined TSS of 0 (none) to 18 (severe)

Time frame:
Until the end of Birch Pollen Season, up to Week 16
Reported as:
Least squares mean · Scores on a Scale
Total Symptom Score (TSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo
Scores on a ScaleREGN5713-5714-5715Placebo Only
Total Symptom Score (TSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo5.19 ± 0.3975.62 ± 0.396
SecondaryTotal Nasal Symptom Score (TNSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo

Total nasal symptom score (TNSS) is from 0 to 12 and is based on assessment of 4 nasal symptoms graded on a Likert scale ranging from 0 (none) to 3 (severe) for congestion, itching, and rhinorrhea, and from 0 (none) to 3 (5 or more sneezes) for sneezing.

Time frame:
Until the end of Birch Pollen Season, up to Week 16
Reported as:
Least squares mean · Score on a scale
Total Nasal Symptom Score (TNSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo
Score on a scaleREGN5713-5714-5715Placebo Only
Total Nasal Symptom Score (TNSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo3.76 ± 0.2784.00 ± 0.277
SecondaryTotal Ocular Symptom Score (TOSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo

Total ocular symptom score is 0 to 6 and is based on itching/redness/gritty feeling and tearing/watering; each of the 2 symptoms is graded 0 (absent), 1 (mild), 2 (moderate), and 3 (severe)

Time frame:
Until the end of Birch Pollen Season, up to Week 16
Reported as:
Least squares mean · Score on a scale
Total Ocular Symptom Score (TOSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo
Score on a scaleREGN5713-5714-5715Placebo Only
Total Ocular Symptom Score (TOSS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo1.43 ± 0.1501.62 ± 0.150
SecondaryDaily Medication Score (DMS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo

The Daily Medication Score (DMS) is calculated by adding points for each pre-specified medication taken as follows: desloratadine 5 mg 6 points/dose; maximum daily score 6 points, olopatadine 1 mg/mL each drop 1.5 points/drop; maximum daily score 6 points, mometasone furoate 50 ug/dose 2.0 points/spray; maximum daily score 8 points). The scale is 0 (minimum) to 20 (maximum)

Time frame:
Until the end of Birch Pollen Season, up to Week 16
Reported as:
Least squares mean · Score on a Scale
Daily Medication Score (DMS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo
Score on a ScaleREGN5713-5714-5715Placebo Only
Daily Medication Score (DMS), Averaged Over the Duration of the Birch Pollen Season, in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo2.316 ± 0.39932.882 ± 0.3986
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) Throughout the Study

Number of participants with any Treatment Emergent Adverse Events (TEAEs) from participating in study

Time frame:
Up to Day 127
Reported as:
Number · Count of Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Throughout the Study
Count of ParticipantsREGN5713-5714-5715Placebo Only
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Throughout the Study9285
SecondaryNumber of Participants With Serious TEAEs Throughout the Study

Number of participants with any Serious Treatment Emergent Adverse Events (TEAEs) from participating in study

Time frame:
Up to Day 127
Reported as:
Number · Count of Participants
Number of Participants With Serious TEAEs Throughout the Study
Count of ParticipantsREGN5713-5714-5715Placebo Only
Number of Participants With Serious TEAEs Throughout the Study30
SecondaryChange From Baseline to the End of Study in Birch SPT Mean Wheal Diameter in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo

Number of participants who showed change from baseline to the end of the study in Birch Skin Prick Test (SPT) Mean Wheal Diameter, in participants who received REGN5713-5714-5715 compared to placebo

Time frame:
Baseline through Day 127
Reported as:
Least squares mean · millimeters
Change From Baseline to the End of Study in Birch SPT Mean Wheal Diameter in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo
millimetersREGN5713-5714-5715Placebo Only
Change From Baseline to the End of Study in Birch SPT Mean Wheal Diameter in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo-3.139 ± 0.50860.553 ± 0.5067
SecondaryPercent Change From Baseline to the End of Study in Birch SPT Mean Wheal Diameter in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo
Time frame:
Baseline through Day 127
Reported as:
Least squares mean · Percentage
Percent Change From Baseline to the End of Study in Birch SPT Mean Wheal Diameter in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo
PercentageREGN5713-5714-5715Placebo Only
Percent Change From Baseline to the End of Study in Birch SPT Mean Wheal Diameter in Participants Who Receive a Single Dose of REGN5713-5714-5715 Versus Placebo-26.38 ± 5.1798.17 ± 5.160
SecondarySerum Concentration of REGN5713 Over the Study Duration
Time frame:
Day 0, Day 56, Day 112
Reported as:
Mean · mg/L
Serum Concentration of REGN5713 Over the Study Duration
mg/LREGN5713-5714-5715
Day 00 ± 0
Day 5610.0 ± 3.97
Day 1122.53 ± 1.57
SecondarySerum Concentration of REGN5714 Over the Study Duration
Time frame:
Up to Day 127
Reported as:
Mean · mg/L
Serum Concentration of REGN5714 Over the Study Duration
mg/LREGN5713-5714-5715
Day 00 ± 0
Day 5614.7 ± 4.68
Day 1124.82 ± 2.16
SecondarySerum Concentration of REGN5715 Over the Study Duration
Time frame:
Up to Day 127
Reported as:
Mean · mg/L
Serum Concentration of REGN5715 Over the Study Duration
mg/LREGN5713-5714-5715
Day 00 ± 0
Day 5616.6 ± 5.34
Day 1125.34 ± 2.35
SecondaryPercentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5713 Throughout the Study

Percentage of participants who developed antibodies to intervention provided during study

Time frame:
Up to Day 127
Reported as:
Number · Percentage of Participants
Percentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5713 Throughout the Study
Percentage of ParticipantsREGN5713-5714-5715Placebo Only
Percentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5713 Throughout the Study00
SecondaryPercentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5714 Throughout the Study

Percentage of participants who developed antibodies to intervention provided during study

Time frame:
Up to Day 127
Reported as:
Number · Percentage of Participants
Percentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5714 Throughout the Study
Percentage of ParticipantsREGN5713-5714-5715Placebo Only
Percentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5714 Throughout the Study00
SecondaryPercentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5715 Throughout the Study

Percentage of participants who developed antibodies to intervention provided during study

Time frame:
Up to Day 127
Reported as:
Number · Percentage of Participants
Percentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5715 Throughout the Study
Percentage of ParticipantsREGN5713-5714-5715Placebo Only
Percentage of Participants With Treatment Emergent Anti-drug Antibodies to REGN5715 Throughout the Study00
SecondaryNumber of "Well Days"

"Well Days" are defined as days when rescue medication is not utilized and the Total symptom score (TSS) is ≤2/18

Time frame:
Until the end of Birch Pollen Season, up to Week 16
Reported as:
Least squares mean · Days
Number of "Well Days"
DaysREGN5713-5714-5715Placebo Only
Number of "Well Days"8.3 ± 1.428.6 ± 1.42

Adverse events

Collected over 28 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/176 (0%)0/176 (0%)43/176 (24.4%)
R5713-5714-5715 900 mg0/173 (0%)3/173 (1.7%)32/173 (18.5%)
Most frequent serious events
Most frequent serious events
EventPlaceboR5713-5714-5715 900 mg
AppendicitisInfections and infestations0/1761/173
Thermal burnInjury, poisoning and procedural complications0/1761/173
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1761/173
Most frequent other events
Most frequent other events
EventPlaceboR5713-5714-5715 900 mg
Vaccination complicationInjury, poisoning and procedural complications22/17617/173
HeadacheNervous system disorders19/17615/173
NasopharyngitisInfections and infestations9/1765/173

Baseline characteristics

Age, Continuous
Age, Continuous(years)REGN5713-5714-5715Placebo OnlyTotal
Mean39.6 ± 14.1542.1 ± 14.3640.9 ± 14.29
Sex: Female, Male
Sex: Female, Male(Participants)REGN5713-5714-5715Placebo OnlyTotal
Female102102204
Male7475149
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)REGN5713-5714-5715Placebo OnlyTotal
Hispanic or Latino224
Not Hispanic or Latino172174346
Unknown or Not Reported213
Race (NIH/OMB)
Race (NIH/OMB)(Participants)REGN5713-5714-5715Placebo OnlyTotal
American Indian or Alaska Native011
Asian31013
Native Hawaiian or Other Pacific Islander101
Black or African American123
White165161326
More than one race000
Unknown or Not Reported639
08

Study locations

37 sites
  • Regeneron Study Site
    Bangor, Maine 04401, United States
  • Regeneron Study Site
    Baltimore, Maryland 21224, United States
  • Regeneron Study Site
    Plymouth, Minnesota 55441, United States
  • Regeneron Study Site
    Columbia, Missouri 65212, United States
  • Regeneron Study Site
    Saint Louis, Missouri 63141, United States
  • Regeneron Study Site
    Missoula, Montana 59808, United States
  • Regeneron Study Site
    Verona, New Jersey 07044, United States
  • Regeneron Study Site
    Great Neck, New York 11021, United States
  • Regeneron Study Site
    Cincinnati, Ohio 45231, United States
  • Regeneron Study Site
    Toledo, Ohio 43617, United States
  • Regeneron Study Site
    Portland, Oregon 97202, United States
  • Regeneron Study Site
    Pittsburgh, Pennsylvania 15241, United States
  • Regeneron Study Site
    Lincoln, Rhode Island 02865, United States
  • Regeneron Study Site
    Greenfield, Wisconsin 53228, United States
  • Regeneron Study Site
    Gent, Oost-Vlaanderen 9000, Belgium
  • Regeneron Study Site
    Leuven, Vlaams Brabant 3000, Belgium
  • Regeneron Study Site
    Kingston, Ontario K7L 2V7, Canada
  • Regeneron Study Site
    London, Ontario N5W 6A2, Canada
  • Regeneron Study Site
    Ottawa, Ontario K1G 6C6, Canada
  • Regeneron Study Site
    Toronto, Ontario M4V 1R2, Canada
  • Regeneron Study Site
    Toronto, Ontario M5B 1W8, Canada
  • Regeneron Study Site
    Toronto, Ontario M5G 1E2, Canada
  • Regeneron Study Site
    Trois-Rivieres, Quebec G8T 7A1, Canada
  • Regeneron Study Site
    Quebec, G1V 4M6, Canada
  • Regeneron Study Site
    Hvidovre, Capital 2650, Denmark
  • Regeneron Study Site
    Hellerup, Copenhagen Surroundings 2900, Denmark
  • Regeneron Study Site
    Vejle, South Jutland 7100, Denmark
  • Regeneron Study Site
    Heidelberg, Baden-Wurttemberg 69120, Germany
  • Regeneron Study Site
    Stuttgart, Baden-Wurttemberg 70374, Germany
  • Regeneron Study Site
    Dreieich, Hessen 63303, Germany
  • Regeneron Study Site
    Wiesbaden, Hessen 65183, Germany
  • Regeneron Study Site
    Duisburg, Nordrhein-Westfalen 47051, Germany
  • Regeneron Study Site
    Dusseldorf, North Rhine-Westphalia 40225, Germany
  • Regeneron Study Site
    Dresden, Sachsen 01139, Germany
  • Regeneron Study Site
    Berlin, 10117, Germany
  • Regeneron Study Site
    Berlin, 14050, Germany
  • Regeneron Study Site
    Hamburg, 22549, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Aug 2021, 7 months.

Results were first posted in Oct 2022, 1 year 2 months after primary completion.

Of 31 industry-sponsored phase 3 interventional studies under Rhinitis, Allergic, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 41. This study's 7 months is below that.

Counting every sponsor, half of 41 studies reached it within 13 months; a quarter within 6 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2020
First posted
Jan 14, 2021
StartActual
Jan 14, 2021
Primary completionActual
Aug 24, 2021
CompletionActual
Aug 24, 2021
Results first posted
Oct 27, 2022
Last update
Oct 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04709575
Responsible party
Sponsor
First posted
Jan 14, 2021
Start date
Jan 14, 2021
Primary completion
Aug 24, 2021
Completion
Aug 24, 2021
Results posted
Oct 27, 2022
Last update
Oct 27, 2022

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bremzalerbart · Atisnolerbart

Start the discussion